Shuro Nishio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuro Nishio has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Daisuke Fukao
Department of Pediatrics, Japanese Red Cross Society, Wakayama Medical Center
1 shared publication- Hirohito Kubota
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto
1 shared publication - Itaru Kato
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto
1 shared publication - Junko Takita
Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Katsutsugu Umeda
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto
1 shared publication - Kimiyoshi Sakaguchi
Department of Pediatrics Hamamatsu University School of Medicine Hamamatsu Japan
1 shared publication
Latest Publications
- 29 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , 385-387
High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma
Background: GD2 is also expressed in normal ocular structures; however, much remains unknown about the risk factors for ocular adverse effects AEs following anti-GD2 immunotherapy remain unknown. Observations: We retrospectively analyzed risk factors for ocular AEs in 9 high-risk neuroblastoma patients. One of the 6 patients who underwent autologous hematopoietic cell transplantation (HCT) alone developed ocular AEs, whereas all 3 patients undergoing tandem autologous-allogeneic HCT did. Other variables, including age, history of anti-GD2 immunotherapy, and preimmunotherapy disease status, showed no significant association with ocular AEs. Conclusions: Allogeneic HCT before anti-GD2 immunotherapy may be a risk factor for ocular AEs.
- 29 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , 385-387
High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma
Background: GD2 is also expressed in normal ocular structures; however, much remains unknown about the risk factors for ocular adverse effects AEs following anti-GD2 immunotherapy remain unknown. Observations: We retrospectively analyzed risk factors for ocular AEs in 9 high-risk neuroblastoma patients. One of the 6 patients who underwent autologous hematopoietic cell transplantation (HCT) alone developed ocular AEs, whereas all 3 patients undergoing tandem autologous-allogeneic HCT did. Other variables, including age, history of anti-GD2 immunotherapy, and preimmunotherapy disease status, showed no significant association with ocular AEs. Conclusions: Allogeneic HCT before anti-GD2 immunotherapy may be a risk factor for ocular AEs.